This is the authors' abstract. We don't add key points for this paper.
Allogeneic cell therapy products, such as therapeutic cells derived from pluripotent stem cells (PSCs), have amazing potential to treat a wide variety of diseases and vast numbers of patients globally. However, there are various challenges related to manufacturing PSCs in single-use bioreactors, particularly at larger volumetric scales. This manuscript addresses these challenges and presents potential solutions to alleviate the anticipated bottlenecks for commercial-scale manufacturing of high-quality therapeutic cells derived from PSCs.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: